NSAIDS Flashcards
What is the most important pharmacokinetic aspect of NSAIDS and what are the implications of this
All are highly protein bound: 90 - 99%
- Overdose: binding sites all quickly saturated –> increase free fraction
- -> total drug levels are not meaningful (? free vs bound)
- -> More free drug to cause toxic effects
- -> More free drug for removal by dialysis - May displace other protein bound drugs changing the free concentration of those
What is the overall oral bioavailability for NSAIDS
Sluggish hepatic metabolism means excellent oral bioavailability 80 - 100 %
How are NSAIDS metabolised and excreted. What are the exceptions.
Hepatic metabolism (CYP3A and CYP2C) –> water soluble conjugates –> renal excretion.
Exceptions:
- Diclofenac
- -> 70% hepatic metabolism then renal excretion
- -> 30% cleared by biliary clearance: enterohepatic circulation (gut bacteria break down glucoronides –> liberating original drug molecule for reabsorption. - Paracoxib (Pro-drug) rapidly metabolized by liver into Valdecoxib (20 seconds). Valdecoxib is then metabolized like other NSAIDS.
Why is the fact that NSAIDS are weak acids important
Alkalinizing the urine can trap the NSAID in the tubule (ionized) and enhance excretion of free drug in the context of toxicity
Why is the enterohepatic recirculation of diclofenac relevant
In the context of toxicity, multi-dose activated charcoal administration is indicated
Name and describe the function of the two most important isoforms of cycloxygenase
COX -1 = ‘Constitutive’ present in all tissues has a housekeeping funciton –> maintain various homeostatic baselines
GIT
E2 –> HCO3- mucus secretion in gastric mucosa
I2 –> HCO3- mucus secretion in gastric mucosa
PLATELETS
A2 –> Increase Platelet aggregation
I2 –> Decrease Platelet aggregation + Vasodilation
RENAL
E2 - Increase RBF (Vasodilation)
I2 - Increase RBF (Vasodilation)
COX-2 = Inducible enzyme (by IL-1, TNF alpha)
INFLAMED TISSUE
E2 –> Incr: vasc. permeability, oedema, nociception
I2 –> Incr: vasc. permeability, oedema, nociception
HYPOTHALAMUS
E2 –> Increase Tb set point (fever)
How do NSAIDS bring about analgaesia
Prostaglandins bind to nociceptor nerve endings (via G protein couple receptors) –> INCREASING the SENSITIVITY of the nociceptors to inflammatory stimuli: bradykinin and histamine.
NSAIDS decrease PG synthesis decreasing the sensitivity of nociceptors
List the adverse effects of NSAIDS
BOTH Selective COX 2 and Non-selective COX inhibitors
- Cardiovascular Event (MI/Stroke)
- MI/Stroke
- Increase BP
- Accelerate atherosclerosis
- Decrease cardioprotection of statins - Nephrotoxicity
- Excessive vasoconstriction –> reduced GFR –> AKI - Exacerbation CCF
- Reduced GFR –> Activation RAAS —> fluid retention + HPT (angiotensin)
- NSAIDS double risk of hospitalization for CCF
Non-selective COX inhibitors only
- Gastric ulceration
- Chronic NSAID = 4 - 5 x higher risk of GI bleeding
- Enteric administration = even higher risk (ion trapping)
What is the difference between eicosanoids and prostanoids
Eicosanoids = Prostaglandins + Leukotrienes
Prostanoids = Prostaglandins
Differentiate COX 1, COX 2 and COX 3
COX 1
- Constitutively expressed in most tissues
- Housekeeping functions: GIT, Plts, RBF
(can be induced during cell differentiation and angiogenesis)
COX 2
- Induced by inflammation (interferon, IL1, TNF), hormones, hypoxia
COX 3
- No prostaglandin producing activity
How do NSAIDS bring about:
- Anti-inflammatory
- Analgaesic
- Antipyretic effects
- Anti-inflammatory - Block PGE2 and PGI2 synthesis (reduced VD and oedema)
- Analgaesia - Reduced PGE2, PGI2 –> reduced sensitization of nociceptors to inflammatory stimuli (bradykinin and histamine)
- Antipyretic - Blocks PGE2 mediated change in set point body temperature in the hypothalamus
What are the important pharmacokinetic properties of NSAIDS
Lipid soluble weak acids
Completely absorbed GIT
Highly protein bound (90 - 99%)
Half life varies 2 - 8 hours
What % of patients on chronic NSAIDS develop GIT bleeding
1 - 3%
How do NSAIDS elicit GIT erosion, ulceration and bleeding
PGI2 and E2 promote HCO3- rich mucus production i the GIT mucosa.
PGI2 and E2 also inhibit H+ secretion.
How does the risk of GIT ulceration change if patients are on concomitant aspirin
Increases